Bailliere's clinical endocrinology and metabolism最新文献_第4页

Forthcoming issue 即将出版

Bailliere's clinical endocrinology and metabolism Pub Date : 1998-10-01 DOI: 10.1016/S0950-351X(98)80039-6

引用次数: 0

Therapeutic role of androgens in the treatment of osteoporosis in men 雄激素在治疗男性骨质疏松症中的作用

Bailliere's clinical endocrinology and metabolism Pub Date : 1998-10-01 DOI: 10.1016/S0950-351X(98)80210-3

MD Laurence Katznelson (Assistant Professor of Medicine, Harvard Medical School)

{"title":"Therapeutic role of androgens in the treatment of osteoporosis in men","authors":"MD Laurence Katznelson (Assistant Professor of Medicine, Harvard Medical School)","doi":"10.1016/S0950-351X(98)80210-3","DOIUrl":"10.1016/S0950-351X(98)80210-3","url":null,"abstract":"<div><p>There has been much recent interest in the relationship between androgens and bone mineralization in men. Increases in serum androgens during puberty allow for skeletal maturation and the attainment of peak bone mass, and the persistence of normal testosterone secretion during adulthood is important for the maintenance of bone density. Testosterone deficiency is associated with heightened bone turnover and is a major risk factor for osteoporosis in men. The administration of testosterone to androgen-deficient men leads to an increase in bone mass, particularly in the trabecular bone compartment, and a reduction in levels of surrogate markers of bone turnover, suggesting that androgens have a dampening effect on bone remodelling. In addition, the administration of androgens to eugonadal men with idiopathic osteoporosis, with resulting supraphysiological testosterone concentrations, may lead to increases in bone mineral density. The risk of osteopenia due to androgen deficiency and the benefits of testosterone substitution therapy or supraphysiological administration on bone will be reviewed.</p></div>","PeriodicalId":77027,"journal":{"name":"Bailliere's clinical endocrinology and metabolism","volume":"12 3","pages":"Pages 453-470"},"PeriodicalIF":0.0,"publicationDate":"1998-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0950-351X(98)80210-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21201388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19

Is there a case for DHEA replacement? 是否有替代脱氢表雄酮的情况?

Bailliere's clinical endocrinology and metabolism Pub Date : 1998-10-01 DOI: 10.1016/S0950-351X(98)80286-3

MD, FACE, FACP Todd B. Nippoldt (Assistant Professor of Medicine), MD, PhD, FRACP(Lond), FACP K. Sreekumaran Nair (Professor of Medicine)

{"title":"Is there a case for DHEA replacement?","authors":"MD, FACE, FACP Todd B. Nippoldt (Assistant Professor of Medicine), MD, PhD, FRACP(Lond), FACP K. Sreekumaran Nair (Professor of Medicine)","doi":"10.1016/S0950-351X(98)80286-3","DOIUrl":"10.1016/S0950-351X(98)80286-3","url":null,"abstract":"<div><p>There are many hormonal changes that occur with ageing in humans, of which the most dramatic and intriguing change occurs for the adrenal androgenic steroid dehydroepiandosterone (DHEA). There are tantalizing epidemiological data demonstrating a significant association between the changes in circulating DHEA level and changes in the incidence of malignancy, atherosclerosis, Alzheimer's disease and other age-related changes. The pharmacological effects in animals such as rodents and rabbits have demonstrated many beneficial effects, for example increased immune function, the prevention of atherosclerosis, cancer, diabetes and obesity, and the improvement of memory. Clinical studies carried out in small groups of subjects have clearly demonstrated that the administration of DHEA to the elderly increases many hormone levels, including that of insulin-like growth factor-1, (free and total) testosterone, dihydrotestosterone, oestrone and oestradiol. It remains to be clearly defined whether these changes are clinically beneficial, and there is only insufficient information on the side-effects on long-term use. Results from short-term intervention studies in small groups of subjects have not demonstrated any convincing beneficial effects so far. A judgement on whether DHEA replacement has a place in preventing age-related disabilities could be determined only on the basis of results from studies of long-term DHEA replacement in elderly people.</p></div>","PeriodicalId":77027,"journal":{"name":"Bailliere's clinical endocrinology and metabolism","volume":"12 3","pages":"Pages 507-520"},"PeriodicalIF":0.0,"publicationDate":"1998-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0950-351X(98)80286-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21201392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 36

Androgen therapy in AIDS wasting 艾滋病的雄激素治疗

Bailliere's clinical endocrinology and metabolism Pub Date : 1998-10-01 DOI: 10.1016/S0950-351X(98)80096-7

MD, MHS Adrian S. Dobs (Associate Professor)

{"title":"Androgen therapy in AIDS wasting","authors":"MD, MHS Adrian S. Dobs (Associate Professor)","doi":"10.1016/S0950-351X(98)80096-7","DOIUrl":"10.1016/S0950-351X(98)80096-7","url":null,"abstract":"<div><p>Hypogonadism in HIV-infected men has been well described, having a prevalence of about 30%. Its aetiology is a combination of non-specific changes from chronic and acute illness, and specific effects due to HIV infection. A depressed serum testosterone level has been associated with viral or infectious invasion of the endocrine organs, and with medications commonly used in treating HIV infection. Recently, many have noted the association between decreased serum testosterone in men and women, and the wasting syndrome of HIV infection, particularly with a reduction in lean body mass. Our understanding of the risks and benefits of testosterone therapy in non-HIV infected men has grown significantly. Treatment in this population can improve sexual function, quality of life parameters and body composition. Based on this information, a few studies have been carried out, and more are being planned to test the hypothesis that therapy with testosterone or its analogues can benefit HIV-infected men and women with wasting and/or low circulating androgen concentrations. To date, the studies have been inconclusive. Not all studies have shown a statistical benefit of androgen therapy on weight, muscle mass or quality of life. Testosterone is now available in several forms for dosing, which has improved compliance and ease of administration. Its potential risks to the prostate or serum lipids should be monitored closely. Although the beneficial effects of androgenic steroids in HIV-infected men have not been demonstrated clearly, short-term studies suggest that testosterone supplementation may improve metabolic outcomes in HIV-infected men with androgen deficiency.</p></div>","PeriodicalId":77027,"journal":{"name":"Bailliere's clinical endocrinology and metabolism","volume":"12 3","pages":"Pages 379-390"},"PeriodicalIF":0.0,"publicationDate":"1998-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0950-351X(98)80096-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21201496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 39

Androgen effects on body composition and muscle function: Implications for the use of androgens as anabolic agents in sarcopenic states 雄激素对身体组成和肌肉功能的影响:在肌肉减少状态下雄激素作为合成代谢剂使用的意义

Bailliere's clinical endocrinology and metabolism Pub Date : 1998-10-01 DOI: 10.1016/S0950-351X(98)80077-3

PhD Rachelle Bross (Fellow), PhD, MD Richard Casaburi (Professor of Medicine Chief), PhD Thomas W. Storer (Professor of Health Science), MD Shalender Bhasin (Professor of Medicine and Chief, Division of Endocrinology, Metabolism and Molecular Medicine)

{"title":"Androgen effects on body composition and muscle function: Implications for the use of androgens as anabolic agents in sarcopenic states","authors":"PhD Rachelle Bross (Fellow), PhD, MD Richard Casaburi (Professor of Medicine Chief), PhD Thomas W. Storer (Professor of Health Science), MD Shalender Bhasin (Professor of Medicine and Chief, Division of Endocrinology, Metabolism and Molecular Medicine)","doi":"10.1016/S0950-351X(98)80077-3","DOIUrl":"10.1016/S0950-351X(98)80077-3","url":null,"abstract":"<div><p>Testosterone-induced nitrogen retention in castrated male animals, eunuchoidal men, prepubertal boys and women, and the sex-related differences in the size of the muscles between male and female animals, have been cited as evidence that testosterone has anabolic effects. Recent studies have reported that replacement doses of testosterone in hypogonadal men and supraphysiological doses in eugonadal men increase fat-free mass, muscle size and strength. These effects have provided the rationale for exploring these anabolic applications in sarcopenic states. Although emerging data demonstrate modest gains in fat-free mass in HIV-infected men given replacement doses of testosterone, we do not know whether testosterone supplementation can produce clinically meaningful changes in muscle function and disease outcome in patients with wasting disorders.</p></div>","PeriodicalId":77027,"journal":{"name":"Bailliere's clinical endocrinology and metabolism","volume":"12 3","pages":"Pages 365-378"},"PeriodicalIF":0.0,"publicationDate":"1998-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0950-351X(98)80077-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21201495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 35

The rationale for physiological testosterone replacement in women 女性生理睾酮替代的基本原理

Bailliere's clinical endocrinology and metabolism Pub Date : 1998-10-01 DOI: 10.1016/S0950-351X(98)80115-8

MBBS, FRACP, PhD Susan R. Davis (Director of Research), MD, FRACP Henry G. Burger (Director)

引用次数: 33

Androgen replacement therapy to reverse and/or prevent age-associated sarcopenia in men 雄激素替代疗法逆转和/或预防男性年龄相关性肌肉减少症

Bailliere's clinical endocrinology and metabolism Pub Date : 1998-10-01 DOI: 10.1016/S0950-351X(98)80153-5

MD, PhD Joyce S. Tenover (Associate Professor of Medicine)

引用次数: 46

Androgen replacement in children with constitutional delay of puberty: The case for aggressive therapy 儿童性发育迟缓的雄激素替代:积极治疗的案例

Bailliere's clinical endocrinology and metabolism Pub Date : 1998-10-01 DOI: 10.1016/S0950-351X(98)80172-9

MD Lisa D. Houchin (Fellow, Division of Pediatric Endocrinology, University of Virginia), MD, PhD Alan D. Rogol (Professor of Pediatrics and Pharmacology University of Virginia)

{"title":"Androgen replacement in children with constitutional delay of puberty: The case for aggressive therapy","authors":"MD Lisa D. Houchin (Fellow, Division of Pediatric Endocrinology, University of Virginia), MD, PhD Alan D. Rogol (Professor of Pediatrics and Pharmacology University of Virginia)","doi":"10.1016/S0950-351X(98)80172-9","DOIUrl":"10.1016/S0950-351X(98)80172-9","url":null,"abstract":"<div><p>Puberty describes the complex physiological transition between childhood and adulthood. Dramatic physical changes occur, most notably the development of secondary sexual characteristics and the pubertal growth spurt. During the adolescent growth spurt, growth velocity increases from pre-pubertal rates of 4–6 cm per year to as much as 10–15 cm per year. Accompanying the increase in gonadal steroids is an increase in amplitude of growth hormone secretory bursts. Evidence suggests that adequate growth hormone and gonadal steroids are both necessary for the attainment of a normal pubertal growth velocity, and the complex interplay between these two hormonal axes is under intense investigation. Delayed onset of puberty, or constitutional delay of growth and adolescence, is a common phenomenon presenting particularly in boys. Physiologically, it represents an extension of the normal pre-pubertal hypogonadotropic hypogonadal state. Without intervention, these children will spontaneously undergo puberty and often reach their genetic height potential, but their delay compared with that of their peers is often of concern to the children and their families. Recent evidence suggests long-term physiological benefits of early androgen replacement therapy in these boys, including maximizing attained bone mineral density. Androgen replacement therapy in male adolescents with constitutional delay of growth and adolescence is beneficial psychologically as well as physiologically and should be initiated promptly.</p></div>","PeriodicalId":77027,"journal":{"name":"Bailliere's clinical endocrinology and metabolism","volume":"12 3","pages":"Pages 427-440"},"PeriodicalIF":0.0,"publicationDate":"1998-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0950-351X(98)80172-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21201500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 24

4 Recombinant human growth hormone as potential therapy for osteoporosis 重组人生长激素作为治疗骨质疏松症的潜在疗法

Bailliere's clinical endocrinology and metabolism Pub Date : 1998-07-01 DOI: 10.1016/S0950-351X(98)80021-9

Robert Marcus MD (Professor of Medicine)

引用次数: 9

Index 指数

Bailliere's clinical endocrinology and metabolism Pub Date : 1998-07-01 DOI: 10.1016/S0950-351X(98)80028-1

引用次数: 0